Teva Unveils Generic Zemplar in US

Teva Pharmaceutical Industries Ltd. TEVA announces the launch of the generic equivalent to Zemplar® (paricalcitol) tablets in the United States as of September 30, 2013. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Zemplar® (paricalcitol) Capsules are an active form of vitamin D used to prevent and treat secondary hyperparathyroidism (increased parathyroid hormone levels) in patients with Stage 3 or Stage 4 chronic kidney disease and in Stage 5 patients on dialysis. It is an active form of vitamin D. Marketed by AbbVie Inc., Zemplar® had annual sales of approximately $115 million in the United States, according to IMS data as of June 30, 2013.